Review



p hdac2 ser394  (Bioss)


Bioz Verified Symbol Bioss is a verified supplier
Bioz Manufacturer Symbol Bioss manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Bioss p hdac2 ser394
    HDAC1, <t>HDAC2</t> and HDAC8 are DUSP26-interacting proteins in chondrocytes. (A) IP/MS analysis in DUSP26-overexpressing chondrocytes under IL-1β stimulation. (B) Flow chart of target protein screening. (C) Immunohistochemical staining of HDAC1, HDAC2 and HDAC8 in the acetabular cartilage of the 4-week-old control rats and rats with DDH. (D) Protein expression levels of HDAC1, p-HDAC1, HDAC2, p-HDAC2, HDAC8 and p-HDAC8 in the chondrocytes by western blotting. (E) Co-IP experiments with DUSP26 protein from extracts of IL-1β-treated chondrocytes followed by western blotting with indicated antibodies. DEG, differentially expressed gene; DUSP26, dual-specificity phosphatase 26; HDAC, histone deacetylase; IB, immunoblot; IL, interleukin; IP, immunoprecipitation; LC-MS/MS, liquid chromatography-tandem MS; mRNA-seq, mRNA sequencing; MS, mass spectrometry; p-, phosphorylated.
    P Hdac2 Ser394, supplied by Bioss, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hdac2/HDAC2+(Ser394)+Polyclonal+Antibody/pmc12948554-53-41-46
    Average 94 stars, based on 1 article reviews
    p hdac2 ser394 - by Bioz Stars, 2026-11
    94/100 stars

    Images

    1) Product Images from "DUSP26: Unveiling a critical molecular mediator and therapeutic target in developmental dysplasia of the hip-associated secondary osteoarthritis"

    Article Title: DUSP26: Unveiling a critical molecular mediator and therapeutic target in developmental dysplasia of the hip-associated secondary osteoarthritis

    Journal: International Journal of Molecular Medicine

    doi: 10.3892/ijmm.2026.5776

    HDAC1, HDAC2 and HDAC8 are DUSP26-interacting proteins in chondrocytes. (A) IP/MS analysis in DUSP26-overexpressing chondrocytes under IL-1β stimulation. (B) Flow chart of target protein screening. (C) Immunohistochemical staining of HDAC1, HDAC2 and HDAC8 in the acetabular cartilage of the 4-week-old control rats and rats with DDH. (D) Protein expression levels of HDAC1, p-HDAC1, HDAC2, p-HDAC2, HDAC8 and p-HDAC8 in the chondrocytes by western blotting. (E) Co-IP experiments with DUSP26 protein from extracts of IL-1β-treated chondrocytes followed by western blotting with indicated antibodies. DEG, differentially expressed gene; DUSP26, dual-specificity phosphatase 26; HDAC, histone deacetylase; IB, immunoblot; IL, interleukin; IP, immunoprecipitation; LC-MS/MS, liquid chromatography-tandem MS; mRNA-seq, mRNA sequencing; MS, mass spectrometry; p-, phosphorylated.
    Figure Legend Snippet: HDAC1, HDAC2 and HDAC8 are DUSP26-interacting proteins in chondrocytes. (A) IP/MS analysis in DUSP26-overexpressing chondrocytes under IL-1β stimulation. (B) Flow chart of target protein screening. (C) Immunohistochemical staining of HDAC1, HDAC2 and HDAC8 in the acetabular cartilage of the 4-week-old control rats and rats with DDH. (D) Protein expression levels of HDAC1, p-HDAC1, HDAC2, p-HDAC2, HDAC8 and p-HDAC8 in the chondrocytes by western blotting. (E) Co-IP experiments with DUSP26 protein from extracts of IL-1β-treated chondrocytes followed by western blotting with indicated antibodies. DEG, differentially expressed gene; DUSP26, dual-specificity phosphatase 26; HDAC, histone deacetylase; IB, immunoblot; IL, interleukin; IP, immunoprecipitation; LC-MS/MS, liquid chromatography-tandem MS; mRNA-seq, mRNA sequencing; MS, mass spectrometry; p-, phosphorylated.

    Techniques Used: Protein-Protein interactions, Immunohistochemical staining, Staining, Control, Expressing, Western Blot, Co-Immunoprecipitation Assay, Histone Deacetylase Assay, Immunoprecipitation, Liquid Chromatography with Mass Spectroscopy, Liquid Chromatography, Sequencing, Mass Spectrometry

    Inactivation of HDAC1/2/8 inhibits DUSP26 silencing-triggered cartilage degeneration. (A) Total protein and phosphorylation levels of HDAC1, HDAC2 and HDAC8 in IL-1β-treated chondrocytes determined by western blotting. (B) Relative mRNA expression levels of HDAC1, HDAC2 and HDAC8 in chondrocytes, as determined by reverse transcription-quantitative PCR. (C) Relative mRNA expression levels of COL1A1 and TNF-α in IL-1β-treated chondrocytes after knocking down HDAC1/2/8. (D) Relative mRNA expression levels of COL1A1 and TNF-α in IL-1β-treated chondrocytes after intervention with the HDAC inhibitor TSA. (E) Protein levels of COL1A1 and TNF-α in IL-1β-treated chondrocytes after knocking down HDAC1/2/8. (F) Protein levels of COL1A1 and TNF-α in IL-1β-treated chondrocytes after intervention with the HDAC inhibitor TSA. Data are presented as the mean ± SD. * P<0.05, ** P<0.01 and *** P<0.001. (B-D) Representative results of three independent experiments are shown. COL1A1, type I collagen; DUSP26, dual-specificity phosphatase 26; HDAC, histone deacetylase; IL, interleukin; NC, negative control; ns, no significance; sh, short hairpin; TSA, trichostatin A.
    Figure Legend Snippet: Inactivation of HDAC1/2/8 inhibits DUSP26 silencing-triggered cartilage degeneration. (A) Total protein and phosphorylation levels of HDAC1, HDAC2 and HDAC8 in IL-1β-treated chondrocytes determined by western blotting. (B) Relative mRNA expression levels of HDAC1, HDAC2 and HDAC8 in chondrocytes, as determined by reverse transcription-quantitative PCR. (C) Relative mRNA expression levels of COL1A1 and TNF-α in IL-1β-treated chondrocytes after knocking down HDAC1/2/8. (D) Relative mRNA expression levels of COL1A1 and TNF-α in IL-1β-treated chondrocytes after intervention with the HDAC inhibitor TSA. (E) Protein levels of COL1A1 and TNF-α in IL-1β-treated chondrocytes after knocking down HDAC1/2/8. (F) Protein levels of COL1A1 and TNF-α in IL-1β-treated chondrocytes after intervention with the HDAC inhibitor TSA. Data are presented as the mean ± SD. * P<0.05, ** P<0.01 and *** P<0.001. (B-D) Representative results of three independent experiments are shown. COL1A1, type I collagen; DUSP26, dual-specificity phosphatase 26; HDAC, histone deacetylase; IL, interleukin; NC, negative control; ns, no significance; sh, short hairpin; TSA, trichostatin A.

    Techniques Used: Phospho-proteomics, Western Blot, Expressing, Reverse Transcription, Real-time Polymerase Chain Reaction, Histone Deacetylase Assay, Negative Control

    Related Articles

    Histone Deacetylase Assay:

    Article Title: DUSP26: Unveiling a critical molecular mediator and therapeutic target in developmental dysplasia of the hip‑associated secondary osteoarthritis.
    Article Snippet: After blocking with 1% bovine serum albumin (BSA; cat. no. A602440‐0050; Sangon Biotech Co., Ltd.) for 15 min at room temperature, the sections were incubated with primary antibodies overnight at 4 ̊C, each diluted to a ratio of 1:200. .. These antibodies included those specific for DUSP26 (cat. no. bs‐7910R; BIOSS), COL2A1 (cat. no. AF0135; Affinity Biosciences), histone deacetylase (HDAC)1 (cat. no. AF6433; Affinity Biosciences), phosphorylated (p)‐HDAC1 (Ser421) (cat. no. PA5‐36810; Thermo Fisher Scientific, Inc.), HDAC2 (cat. no. AF6470; Affinity Biosciences), p‐HDAC2 (Ser394) (cat. no. bs‐5389R; BIOSS), HDAC8 (cat. no. AF6481; Affinity Biosciences) and p‐HDAC8 (Ser39) (cat. no. AF3481; Affinity Biosciences). .. Following an extensive washing process in PBS, the sections were incubated with a horseradish peroxidase (HRP)‐conjugated secondary antibody (cat. no. SE134; Beijing Solarbio Science & Technology Co., Ltd.) at dilution of 1:100 in PBS at 37 ̊C for 45 min followed by a staining with 3,3'‐diami‐ nobenzidine.

    Article Title: DUSP26: Unveiling a critical molecular mediator and therapeutic target in developmental dysplasia of the hip-associated secondary osteoarthritis
    Article Snippet: After blocking with 1% bovine serum albumin (BSA; cat. no. A602440-0050; Sangon Biotech Co., Ltd.) for 15 min at room temperature, the sections were incubated with primary antibodies overnight at 4°C, each diluted to a ratio of 1:200. .. These antibodies included those specific for DUSP26 (cat. no. bs-7910R; BIOSS), COL2A1 (cat. no. AF0135; Affinity Biosciences), histone deacetylase (HDAC)1 (cat. no. AF6433; Affinity Biosciences), phosphorylated (p)-HDAC1 (Ser421) (cat. no. PA5-36810; Thermo Fisher Scientific, Inc.), HDAC2 (cat. no. AF6470; Affinity Biosciences), p-HDAC2 (Ser394) (cat. no. bs-5389R; BIOSS), HDAC8 (cat. no. AF6481; Affinity Biosciences) and p-HDAC8 (Ser39) (cat. no. AF3481; Affinity Biosciences). .. Following an extensive washing process in PBS, the sections were incubated with a horseradish peroxidase (HRP)-conjugated secondary antibody (cat. no. SE134; Beijing Solarbio Science & Technology Co., Ltd.) at dilution of 1:100 in PBS at 37°C for 45 min followed by a staining with 3,3'-diaminobenzidine.



    Similar Products

    95
    MedChemExpress hdac2 inhibition assay
    Hdac2 Inhibition Assay, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hdac2/HDAC2+Antibody/pm42965736-55-24-34
    Average 95 stars, based on 1 article reviews
    hdac2 inhibition assay - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    91
    Sino Biological hdac2
    Hdac2, supplied by Sino Biological, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hdac2/HDAC2%2C+Active/pm42911727-341-10-11
    Average 91 stars, based on 1 article reviews
    hdac2 - by Bioz Stars, 2026-11
    91/100 stars
      Buy from Supplier

    94
    BPS Bioscience hdac2
    Hdac2, supplied by BPS Bioscience, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hdac2/HDAC2%2C+His-tag+Recombinant/pm42994190-549-4-28
    Average 94 stars, based on 1 article reviews
    hdac2 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    95
    Proteintech hdac2
    Hdac2, supplied by Proteintech, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hdac2/HDAC2+Antibody/pm42929872-128-94-96
    Average 95 stars, based on 1 article reviews
    hdac2 - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    96
    Cell Signaling Technology Inc antibodies alpha tubulin dm1a mouse
    Antibodies Alpha Tubulin Dm1a Mouse, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hdac2/HDAC2+Antibody/pm42875546-701-28-27
    Average 96 stars, based on 1 article reviews
    antibodies alpha tubulin dm1a mouse - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    94
    ABclonal Biotechnology anti hdac2
    Anti Hdac2, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hdac2/HDAC2+Rabbit+mAb/pm42826558-45-203-205
    Average 94 stars, based on 1 article reviews
    anti hdac2 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    BPS Bioscience fluorogenic hdac2 assay kit
    Fluorogenic Hdac2 Assay Kit, supplied by BPS Bioscience, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hdac2/HDAC2+Fluorogenic+Assay+Kit/pm42805174-972-22-26
    Average 94 stars, based on 1 article reviews
    fluorogenic hdac2 assay kit - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    95
    Proteintech antibodies against hdac2
    A simple yet powerful label-free strategy was developed to directly convert drug molecules into fluorescent probes, enabling cellular imaging and orchestrating a lysosome-mitochondria-nucleus interplay that elicits nuclear ROS (nuROS) generation. This, in turn, activates an uncharacterized <t>nuROS-HDAC2-EMT</t> axis, thereby abrogating metastasis.
    Antibodies Against Hdac2, supplied by Proteintech, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hdac2/HDAC2+Antibody/pmc13634123-177-18-22
    Average 95 stars, based on 1 article reviews
    antibodies against hdac2 - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    95
    Cell Signaling Technology Inc hdac2 3f3 mouse
    A simple yet powerful label-free strategy was developed to directly convert drug molecules into fluorescent probes, enabling cellular imaging and orchestrating a lysosome-mitochondria-nucleus interplay that elicits nuclear ROS (nuROS) generation. This, in turn, activates an uncharacterized <t>nuROS-HDAC2-EMT</t> axis, thereby abrogating metastasis.
    Hdac2 3f3 Mouse, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hdac2/HDAC2+Mouse+mAb/10__1038_slash_s42003___026___10753___4-295-104-107
    Average 95 stars, based on 1 article reviews
    hdac2 3f3 mouse - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    Image Search Results


    A simple yet powerful label-free strategy was developed to directly convert drug molecules into fluorescent probes, enabling cellular imaging and orchestrating a lysosome-mitochondria-nucleus interplay that elicits nuclear ROS (nuROS) generation. This, in turn, activates an uncharacterized nuROS-HDAC2-EMT axis, thereby abrogating metastasis.

    Journal: Materials Today Bio

    Article Title: A label-free supramolecular nanoassembly triggers multi-organelle crosstalk-dependent metastasis inhibition via nuclear ROS-HDAC2 axis

    doi: 10.1016/j.mtbio.2026.103681

    Figure Lengend Snippet: A simple yet powerful label-free strategy was developed to directly convert drug molecules into fluorescent probes, enabling cellular imaging and orchestrating a lysosome-mitochondria-nucleus interplay that elicits nuclear ROS (nuROS) generation. This, in turn, activates an uncharacterized nuROS-HDAC2-EMT axis, thereby abrogating metastasis.

    Article Snippet: In the immunohistochemical analysis, the sections were incubated with 3% BSA for 30 min before being exposed to antibodies against HDAC2 (1:2000; Proteintech, 12922-3-AP), E-cadherin (1:300; Immunoway, YT1454) or Vimentin (1:300; Immunoway, YT5796).

    Techniques: Imaging

    The supratargeting mechanism through proteomics analysis. (a) Volcano plots of differentially expressed proteins (DEPs) in 4T1 cells treated with Control or diNP@PDs (25 μM). Proteins are represented by dots, with upregulated proteins highlighted in red and downregulated proteins in blue. (b) Proteomics analysis showing DEPs in distinct subcellular compartments of 4T1 cells treated with Control or diNP@PDs. The subcellular structure annotations for DEPs were classified based on Gene Ontology (GO) analysis. (c) PRM-based proteomic profiling elucidates multi-organelle targeting mechanism of diNP@PDs. Through high-resolution parallel reaction monitoring (PRM) targeted proteomics. (d-e) GO enrichment analysis of up-regulated (d) and down-regulated (e) genes in diNP@PDs compared to control groups. (f-g) GSEA enrichment analysis (f) and KEGG pathway (g) of lysosome-related genes. (h,i) Circos plots of upregulated ( h ) or downregulated ( i ) DEPs and their associated enriched pathways. (j) Venn diagram of the most differential survival genes from GEPIA2, DEPs and proteins relative to L-M-N. (k) Relative protein levels of 27 proteins located in lysosomes, mitochondria, and nuclei identified via Venn diagram. (l ) Survival analysis plots of nuclear HDAC2 in breast invasive carcinoma (BRCA) patients using the GEPIA database ( http://gepia.cancer-pku.cn/ ). (m ) A Gene Set Enrichment Analysis (GSEA) for pathway enrichment of Reactive Oxygen Species based on identified DEPs, represented by normalized enrichment score (NES) and nominal p value.

    Journal: Materials Today Bio

    Article Title: A label-free supramolecular nanoassembly triggers multi-organelle crosstalk-dependent metastasis inhibition via nuclear ROS-HDAC2 axis

    doi: 10.1016/j.mtbio.2026.103681

    Figure Lengend Snippet: The supratargeting mechanism through proteomics analysis. (a) Volcano plots of differentially expressed proteins (DEPs) in 4T1 cells treated with Control or diNP@PDs (25 μM). Proteins are represented by dots, with upregulated proteins highlighted in red and downregulated proteins in blue. (b) Proteomics analysis showing DEPs in distinct subcellular compartments of 4T1 cells treated with Control or diNP@PDs. The subcellular structure annotations for DEPs were classified based on Gene Ontology (GO) analysis. (c) PRM-based proteomic profiling elucidates multi-organelle targeting mechanism of diNP@PDs. Through high-resolution parallel reaction monitoring (PRM) targeted proteomics. (d-e) GO enrichment analysis of up-regulated (d) and down-regulated (e) genes in diNP@PDs compared to control groups. (f-g) GSEA enrichment analysis (f) and KEGG pathway (g) of lysosome-related genes. (h,i) Circos plots of upregulated ( h ) or downregulated ( i ) DEPs and their associated enriched pathways. (j) Venn diagram of the most differential survival genes from GEPIA2, DEPs and proteins relative to L-M-N. (k) Relative protein levels of 27 proteins located in lysosomes, mitochondria, and nuclei identified via Venn diagram. (l ) Survival analysis plots of nuclear HDAC2 in breast invasive carcinoma (BRCA) patients using the GEPIA database ( http://gepia.cancer-pku.cn/ ). (m ) A Gene Set Enrichment Analysis (GSEA) for pathway enrichment of Reactive Oxygen Species based on identified DEPs, represented by normalized enrichment score (NES) and nominal p value.

    Article Snippet: In the immunohistochemical analysis, the sections were incubated with 3% BSA for 30 min before being exposed to antibodies against HDAC2 (1:2000; Proteintech, 12922-3-AP), E-cadherin (1:300; Immunoway, YT1454) or Vimentin (1:300; Immunoway, YT5796).

    Techniques: Proteomic Assay, Analysis, Control, Profiling, Targeted Proteomics, Gene Set Enrichment Analysis, Significance Assay

    Inhibiting tumor metastasis via HDAC2 sensing nuclear ROS. (a) Representative confocal images of intracellular ROS generation after the indicated treatment. (b) Dose-response relationship of ROS production in 4T1 cells after 24 h treatment with diNP@PDs (5-50 μM). (c) Time-course analysis of ROS generation in 4T1 cells treated with 20 μM diNP@PDs. (d-f) Nuclear ROS (nuROS) in 4T1 cells post-treatment. Quantitative analysis of nuROS levels by flow cytometry (d-e) . Purple bars: nuROS levels after various treatment, measured via DCFH-DA staining; Blue bars: drug fluorescence in the FITC channel after cellular uptake (f) . Nuclear fractions were isolated using a Nuclear Extraction Kit (Solarbio®), following manufacturer's protocol. (g-h) HDAC2 immunofluorescence in 4T1 cells treated with Cur (6.25 μM), Sora (25 μM) and diNP@PDs (25 μM) for 12 h. (i ) Immunoblotting analysis of HDAC2 expression after the indicated treatment. (j ) Flow cytometry analysis of cellular ROS levels after indicated treatments with the ROS inhibitor NAC or diNP@PDs. (k,l ) Representative confocal images ( k ) and mean intensity values ( l ) of cellular immunofluorescence of HDAC2 after indicated treatments with the ROS inhibitor NAC or diNP@PDs. Scale bar, 10 μm. (m-n ) Representative images ( m ) and quantitative analysis ( n ) of wound healing assay to measure the migration ability of the HDAC2 inhibitor SAHA and diNP@PDs. (o ) Schematic illustration of the mechanism underlying tumor metastasis inhibition via the nuROS-HDAC2-EMT pathway. Data are shown as mean ± s.d. Statistical significance of p values in b,c,e,f,h,j,l was calculated via one-way ANOVA with a Tukey post-hoc test, and this in n was calculated by a two-tailed Student's t-test.

    Journal: Materials Today Bio

    Article Title: A label-free supramolecular nanoassembly triggers multi-organelle crosstalk-dependent metastasis inhibition via nuclear ROS-HDAC2 axis

    doi: 10.1016/j.mtbio.2026.103681

    Figure Lengend Snippet: Inhibiting tumor metastasis via HDAC2 sensing nuclear ROS. (a) Representative confocal images of intracellular ROS generation after the indicated treatment. (b) Dose-response relationship of ROS production in 4T1 cells after 24 h treatment with diNP@PDs (5-50 μM). (c) Time-course analysis of ROS generation in 4T1 cells treated with 20 μM diNP@PDs. (d-f) Nuclear ROS (nuROS) in 4T1 cells post-treatment. Quantitative analysis of nuROS levels by flow cytometry (d-e) . Purple bars: nuROS levels after various treatment, measured via DCFH-DA staining; Blue bars: drug fluorescence in the FITC channel after cellular uptake (f) . Nuclear fractions were isolated using a Nuclear Extraction Kit (Solarbio®), following manufacturer's protocol. (g-h) HDAC2 immunofluorescence in 4T1 cells treated with Cur (6.25 μM), Sora (25 μM) and diNP@PDs (25 μM) for 12 h. (i ) Immunoblotting analysis of HDAC2 expression after the indicated treatment. (j ) Flow cytometry analysis of cellular ROS levels after indicated treatments with the ROS inhibitor NAC or diNP@PDs. (k,l ) Representative confocal images ( k ) and mean intensity values ( l ) of cellular immunofluorescence of HDAC2 after indicated treatments with the ROS inhibitor NAC or diNP@PDs. Scale bar, 10 μm. (m-n ) Representative images ( m ) and quantitative analysis ( n ) of wound healing assay to measure the migration ability of the HDAC2 inhibitor SAHA and diNP@PDs. (o ) Schematic illustration of the mechanism underlying tumor metastasis inhibition via the nuROS-HDAC2-EMT pathway. Data are shown as mean ± s.d. Statistical significance of p values in b,c,e,f,h,j,l was calculated via one-way ANOVA with a Tukey post-hoc test, and this in n was calculated by a two-tailed Student's t-test.

    Article Snippet: In the immunohistochemical analysis, the sections were incubated with 3% BSA for 30 min before being exposed to antibodies against HDAC2 (1:2000; Proteintech, 12922-3-AP), E-cadherin (1:300; Immunoway, YT1454) or Vimentin (1:300; Immunoway, YT5796).

    Techniques: Confocal, Analysis, Flow Cytometry, Staining, Fluorescence, Isolation, Extraction, Immunofluorescence, Western Blot, Expressing, Wound Healing Assay, Migration, Inhibition, Two Tailed Test

    diNP@PDs-induced L-M-N contacts in vivo regulate HDAC2 signaling and attenuate metastasis. (a) Schematic illustration of lung metastasis inhibition after being treated with diNP@PDs. (b) Representative bioluminescence images of tumor-bearing mice at specified time points after indicated treatments ( n = 3). (c-d) Immunohistochemical staining ( c ) and quantitative analysis ( d ) of EMT markers after indicated treatment. Scale bar, 25 μm. (e-f) HDAC2 expression in metastatic lungs after indicated treatment. Scale bar, 100 μm. (g) Representative confocal images of L-M-N contacts in metastasis-bearing lungs stained for LAMP1 (lysosome), TOMM20 (mitochondrion), and Lamin B1 (nucleus). Scale bar, 10 μm. Data are shown as mean ± s.d.

    Journal: Materials Today Bio

    Article Title: A label-free supramolecular nanoassembly triggers multi-organelle crosstalk-dependent metastasis inhibition via nuclear ROS-HDAC2 axis

    doi: 10.1016/j.mtbio.2026.103681

    Figure Lengend Snippet: diNP@PDs-induced L-M-N contacts in vivo regulate HDAC2 signaling and attenuate metastasis. (a) Schematic illustration of lung metastasis inhibition after being treated with diNP@PDs. (b) Representative bioluminescence images of tumor-bearing mice at specified time points after indicated treatments ( n = 3). (c-d) Immunohistochemical staining ( c ) and quantitative analysis ( d ) of EMT markers after indicated treatment. Scale bar, 25 μm. (e-f) HDAC2 expression in metastatic lungs after indicated treatment. Scale bar, 100 μm. (g) Representative confocal images of L-M-N contacts in metastasis-bearing lungs stained for LAMP1 (lysosome), TOMM20 (mitochondrion), and Lamin B1 (nucleus). Scale bar, 10 μm. Data are shown as mean ± s.d.

    Article Snippet: In the immunohistochemical analysis, the sections were incubated with 3% BSA for 30 min before being exposed to antibodies against HDAC2 (1:2000; Proteintech, 12922-3-AP), E-cadherin (1:300; Immunoway, YT1454) or Vimentin (1:300; Immunoway, YT5796).

    Techniques: In Vivo, Inhibition, Immunohistochemical staining, Staining, Analysis, Expressing, Confocal

    Journal: Materials Today Bio

    Article Title: A label-free supramolecular nanoassembly triggers multi-organelle crosstalk-dependent metastasis inhibition via nuclear ROS-HDAC2 axis

    doi: 10.1016/j.mtbio.2026.103681

    Figure Lengend Snippet:

    Article Snippet: In the immunohistochemical analysis, the sections were incubated with 3% BSA for 30 min before being exposed to antibodies against HDAC2 (1:2000; Proteintech, 12922-3-AP), E-cadherin (1:300; Immunoway, YT1454) or Vimentin (1:300; Immunoway, YT5796).

    Techniques: